Other substances

Darapladib

A lipoprotein-associated phospholipase-A2 inhibitor

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Darapladib is a pyrimidone inhibitor of lipoprotein-associated phospholipase-A2, which has been implied to play a role during the progression of atherosclerosis (NCIt).

Darapladib on DrugBank
Darapladib on PubChem
Darapladib on Wikipedia


 

Structure image - Darapladib

CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F


 

Supporting references

Link Tested on Impact factor Notes Publication date
Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing
Small molecule In vitro 		in vitro bacteria-based assay 3.82

Displayed inhibitory activity against the potential ion channel ORF3a of SARS-CoV-2 in a bacterial model assay.

 Mar/23/2021
Export (.csv)